Der Kaninchen Polyklonal anti-LEF1 Antikörper wird verwendet zum Nachweis von LEF1 in Proben von Human, Maus und Ratte. Er wurde validiert für WB und IHC.
Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB 1:500-2000,IHC 1:50-300
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
Liquid in PBS containing 50 % glycerol, 0.5 % BSA and 0.02 % sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
-20 °C
Informationen zur Lagerung
Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.
Haltbarkeit
12 months
Target
LEF1
(Lymphoid Enhancer-Binding Factor 1 (LEF1))
Andere Bezeichnung
LEF-1
Hintergrund
LEF1, Lymphoid enhancer-binding factor 1, LEF-1, T cell-specific transcription factor 1-alpha, TCF1-alphaLEF1 (lymphoid enhancer binding factor 1) encodes a transcription factor belonging to a family of proteins that share homology with the high mobility group protein-1. The protein encoded by this gene can bind to a functionally important site in the T-cell receptor-alpha enhancer, thereby conferring maximal enhancer activity. This transcription factor is involved in the Wnt signaling pathway, and it may function in hair cell differentiation and follicle morphogenesis. Mutations in LEF1 have been found in somatic sebaceous tumors. LEF1 has also been linked to other cancers, including androgen-independent prostate cancer. Alternative splicing results in multiple transcript variants.